Lawmakers plan to announce details on their bipartisan infrastructure package as soon as Monday, which will reportedly include delaying a Trump-era Medicare rebate rule in an effort to help offset some costs. Health care provider groups are also furiously pushing back against another floated pay-for: Billions of dollars in emergency money that hasn’t yet been distributed from the Provider Relief Fund. Federal health officials said in late May there was $24 billion left in the fund, but a recent federal watchdog report pinned the total closer to $44 billion.
Maggie Elehwany, senior vice president of public affairs at Argentum, which represents senior living communities, says they’ll continue to lobby lawmakers to look elsewhere for infrastructure bill funding, highlighting that their facilities remain vulnerable given the spike in COVID-19 infections. “This could not be a more short-sighted thought process on Congress’s part,” she said.
The Senate Health, Education, Labor and Pensions Committee will hold a hearing at 10 a.m. Tuesday on the future of the federal response to COVID-19, featuring testimony from health leaders in Washington and Louisiana, as well as a Johns Hopkins global security expert and an infectious diseases policy executive from the Biotechnology Innovation Organization, which represents biotech companies.
The House Energy and Commerce Committee will hold a hearing at 11 a.m. Thursday on advancing treatments for neurodegenerative conditions like Alzheimer’s disease. The hearing comes as Rep. Frank Pallone (D-N.J.), the committee chair, leads an investigation into the approval and pricing of Biogen Inc.’s controversial Alzheimer’s drug.
Amazon.com Inc. is reporting quarterly earnings Thursday, and we’re hoping to get a sense of the company’s plans for Amazon Care, the virtual-first medical service it said it would roll out to employers across the country this summer. We’ll also learn how drugmakers Pfizer Inc., AbbVie Inc, AstraZeneca PLC, Bristol-Myers Squibb Co., Sanofi SA and Merck & Co. fared in the second quarter, along with several other health care companies.